S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
NASDAQ:BWAY

BrainsWay (BWAY) Stock Forecast, Price & News

$4.26
-0.35 (-7.59%)
(As of 09/21/2023 ET)
Compare
Today's Range
$4.10
$4.52
50-Day Range
$2.28
$4.61
52-Week Range
$1.38
$4.85
Volume
117,851 shs
Average Volume
113,080 shs
Market Capitalization
$70.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

BrainsWay MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
56.5% Upside
$6.67 Price Target
Short Interest
Healthy
0.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.40) to ($0.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

624th out of 965 stocks

Surgical & Medical Instruments Industry

68th out of 96 stocks


BWAY stock logo

About BrainsWay (NASDAQ:BWAY) Stock

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

BWAY Price History

BWAY Stock News Headlines

Are Medical Stocks Lagging Brainsway (BWAY) This Year?
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
BrainsWay: Profitability Is Within Sight
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
BrainsWay Expands into India
The Latest Analyst Ratings for BrainsWay
H.C. Wainwright Keeps Their Buy Rating on Brainsway (BWAY)
BrainsWay Appoints Ido Marom To Succeed Scott Areglado As CFO
BrainsWay appoints CFO
BrainsWay Announces Appointment of Ido Marom as CFO
BrainsWay - Aiming For Revenue Growth And Profitability
BrainsWay: Q1 Earnings Insights
Earnings Outlook For BrainsWay
See More Headlines
Receive BWAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter.

BWAY Company Calendar

Last Earnings
8/09/2023
Today
9/22/2023
Next Earnings (Estimated)
11/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BWAY
Fax
N/A
Employees
134
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+56.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-13,350,000.00
Pretax Margin
-49.23%

Debt

Sales & Book Value

Annual Sales
$27.18 million
Book Value
$2.75 per share

Miscellaneous

Free Float
13,445,000
Market Cap
$70.72 million
Optionable
Not Optionable
Beta
0.96
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Hadar Levy (Age 49)
    Chief Exec. Officer
    Comp: $470.16k
  • Mr. Avner Hagai (Age 67)
    Founder & Director
    Comp: $47.37k
  • Prof. Abraham Zangen (Age 53)
    Co-Founder, Member of Scientific Advisory Board & Director
    Comp: $77.2k
  • Mr. Christopher J. Boyer Ph.D. (Age 45)
    VP of Global Marketing
    Comp: $337.95k
  • Dr. Yiftach Roth Ph.D. (Age 52)
    Founder & Chief Scientific Officer
  • Mr. Ido Marom
    Chief Financial Officer
  • Mr. Menachem C. Klein Esq.
    VP, Gen. Counsel & Corp. Sec.
  • Dr. Aron Tendler
    Chief Medical Officer













BWAY Stock - Frequently Asked Questions

Should I buy or sell BrainsWay stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BWAY shares.
View BWAY analyst ratings
or view top-rated stocks.

What is BrainsWay's stock price forecast for 2023?

3 Wall Street analysts have issued 12 month price targets for BrainsWay's shares. Their BWAY share price forecasts range from $3.00 to $12.00. On average, they expect the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 56.5% from the stock's current price.
View analysts price targets for BWAY
or view top-rated stocks among Wall Street analysts.

How have BWAY shares performed in 2023?

BrainsWay's stock was trading at $2.47 at the start of the year. Since then, BWAY stock has increased by 72.5% and is now trading at $4.26.
View the best growth stocks for 2023 here
.

Are investors shorting BrainsWay?

BrainsWay saw a increase in short interest in August. As of August 31st, there was short interest totaling 82,800 shares, an increase of 268.0% from the August 15th total of 22,500 shares. Based on an average daily volume of 50,000 shares, the short-interest ratio is presently 1.7 days.
View BrainsWay's Short Interest
.

When is BrainsWay's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 15th 2023.
View our BWAY earnings forecast
.

How were BrainsWay's earnings last quarter?

BrainsWay Ltd. (NASDAQ:BWAY) issued its earnings results on Wednesday, August, 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.12. The business had revenue of $7.83 million for the quarter, compared to analyst estimates of $7.03 million. BrainsWay had a negative net margin of 50.67% and a negative trailing twelve-month return on equity of 29.12%.

What other stocks do shareholders of BrainsWay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).

When did BrainsWay IPO?

(BWAY) raised $30 million in an IPO on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor served as the underwriter for the IPO.

What is BrainsWay's stock symbol?

BrainsWay trades on the NASDAQ under the ticker symbol "BWAY."

Who are BrainsWay's major shareholders?

BrainsWay's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Worth Venture Partners LLC (1.92%), Psagot Value Holdings Ltd. Israel (0.45%), Citadel Advisors LLC (0.37%), Renaissance Technologies LLC (0.27%) and Good Life Advisors LLC (0.23%).

How do I buy shares of BrainsWay?

Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BrainsWay's stock price today?

One share of BWAY stock can currently be purchased for approximately $4.26.

How much money does BrainsWay make?

BrainsWay (NASDAQ:BWAY) has a market capitalization of $70.72 million and generates $27.18 million in revenue each year. The company earns $-13,350,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does BrainsWay have?

The company employs 134 workers across the globe.

How can I contact BrainsWay?

BrainsWay's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The official website for the company is www.brainsway.com. The company can be reached via phone at (722) 582-4030 or via email at hadarl@brainsway.com.

This page (NASDAQ:BWAY) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -